The objectives of these studies can be grouped into three categories: establishing the serum or tissue level of renalase in different stages of CKD (Table 1), analyzing the value of renalase as a biomarker in CKD (Table 1), and investigating the effect of the therapeutic administration of renalase in patients with CKD (Table 2). The gene discussed is RNLS; the disease is chronic kidney disease.